Brief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
29/07/2026 07:42
BRIEF-Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported July 29 (Reuters) - Allergy Therapeutics PLC AGY.L:
ALLERGY THERAPEUTICS FY REVENUE GBP 59.9 MILLION
ALLERGY THERAPEUTICS - EXPECTS FY 2026 REVENUE OF £59.90 MILLION, UP 9% REPORTED
Source text: ID:nRSc2593Oa
Further company coverage: AGY.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman